{"nctId":"NCT01069705","briefTitle":"Second Open Label Extension to Bridging Study CTBM100C2303","startDateStruct":{"date":"2010-02-12","type":"ACTUAL"},"conditions":["Pulmonary Infections","Pseudomonas Aeruginosa"],"count":49,"armGroups":[{"label":"Tobramycin Inhalation Powder (TIPnew)","type":"EXPERIMENTAL","interventionNames":["Drug: Tobramycin inhalation powder"]}],"interventions":[{"name":"Tobramycin inhalation powder","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed all visits in study CTBM100C2303 and CTBM100C2303E1, and visit 11 of study CTBM100C2303E1 took place not more than 5 days before enrollment into this study.\n* Confirmed diagnosis of cystic fibrosis participants with P. aeruginosa infection.\n* Forced Expiratory Volume in one second (FEV1) at screening (at start of study CTBM100C2303) must be between 25% and 80% of normal predicted values.\n\nExclusion Criteria:\n\n* Any use of inhaled anti-pseudomonal antibiotics between the termination of the trial CTMB100C2303E1 and the enrollment into this study.\n* Known local or systemic hypersensitivity to aminoglycosides or inhaled antibiotics.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"21 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Adverse Events (AEs)","description":"An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not related to study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Decrease of ≥20% in Forced Expiratory Value in One Second (FEV1) Percent (%) Predicted From Pre-dose to 30-minute Post-dose","description":"Airway Reactivity \\>= 20% relative decrease in FEV1% predicted from pre-dose to 30 minutes post-dose. Relative Change = 100 \\* (30 minutes Post-dose - Pre-dose)/Pre-dose assessed by the number and percentage of participants with a decrease of ≥ 20% in FEV1 % predicted from pre-dose to 30 minutes post-dose.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Frequency Decrease From Baseline in the Post-baseline Audiology Tests","description":"Auditory acuity of participants was measured using a standard dual-channel audiometer at frequencies from 250 to 8000 Hertz, and an audiogram (pure-tone air conduction) and tympanogram were performed by an audiologist. The categories reported includes \\>= 10dB decrease in 3 consecutive frequencies in either ear, \\>= 15dB decrease in 2 consecutive frequencies in either ear, and \\>= 20dB decrease in at least one frequency in either ear","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline of Forced Expiratory Volume in One Second (FEV1) Percent Predicted to Each Post-baseline Visit","description":"Forced expiratory volume in one second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 % predicted was a normalized value of FEV1 calculated using the Knudsen equation, based upon participant's age, gender and height. Relative change in FEV1 % predicted from baseline to pre-dose day X = ((pre-dose day X FEV1 % predicted - baseline FEV1 % predicted) / baseline FEV1 % predicted) x 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5","spread":"16.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"21.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"24.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":"19.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"24.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"22.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"26.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"25.79"}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline of Forced Vital Capacity (FVC) Percent Predicted to Each Post-baseline Visit","description":"Percent Predicted Forced Vital Capacity (FVC%) is the maximal exhaled breath volume following a maximal inhaled breath. Overall change in percent predicted FVC = (observed value)/(predicted value) \\* 100%. A higher value indicates a greater response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":"17.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"15.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"17.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"16.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":"20.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"19.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"20.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","spread":"20.37"}]}]}]},{"type":"SECONDARY","title":"Relative Change From Baseline of Forced Expiratory Flow Rate Over 25 and 75 Percent (FEF25-75%) Predicted to Each Post-baseline Visit","description":"Forced Expiratory Flow Rate Over 25 and 75 Percent (FEF25-75%) is the forced expiratory flow from 25% to 75% of the Forced Vital Capacity (FVC). Relative change in FEF25-75% from baseline to pre-dose day X = (pre-dose day X FEF25-75 - baseline FEF25-75) / baseline FEF25-75) • 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":"20.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.7","spread":"57.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.2","spread":"67.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":"66.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.3","spread":"63.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":"80.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":"61.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.6","spread":"77.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pseudomonas Aeruginosa Sputum Density to Each Post-baseline Visit","description":"Pseudomonas Aeruginosa Density refers to overall density, defined as the sum of Biotypes (mucoid, dry and small colony variant). Absolute change was determined using the formula; Change = Post-baseline value- baseline value. Absolute Change in Pseudomonas Aeruginosa Sputum density is measured in log 10 Colony Forming Units per gram (Log 10 CFU/g).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"1.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"2.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"2.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"2.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"3.62"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Tobramycin Minimum Inhibitory Concentration (MIC) Values for Pseudomonas Aeruginosa to Each Post-baseline Visit","description":"Minimum Inhibitory Concentration (MIC) is defined as the lowest concentration of an antimicrobial agent required to inhibit the visible growth of a microorganism after overnight incubation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"9.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.4","spread":"117.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":"92.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":"138.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":"94.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"22.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":"115.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"11.14"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Used New Antipseudomonal Antibiotic During Treatment Period","description":"The rate of anti-pseudomonal antibiotics use were determined from the collection of concomitant medication during the study Treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hospitalization Due to Respiratory Serious Adverse Events (SAEs)","description":"A SAE was defined as an event which was fatal or life threatening, required or prolonged hospitalization, was significantly or permanently disabling or incapacitating, constituted a congenital anomaly or a birth defect, or encompassed any other clinically significant event that could jeopardize the participant or require medical or surgical intervention to prevent one of the aforementioned outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days of Hospitalization Due to Respiratory Serious Adverse Events (SAEs)","description":"The average number of days patients were hospitalized due to respiratory events during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"2.12"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":49},"commonTop":["Respiratory tract infection","Respiratory tract infection viral","Bronchitis","Cough","Hypoacusis"]}}}